

A case of neuropsychiatric lupus with myelopathy successfully treated with corticosteroids

Homeed H. Salmi*, Medhat A.F. Shalaby**, Hussein M. Ageely*, and Fayza Moustafa***

Departments of Internal Medicine*, Rheumatology** and Microbiology***

Assir Central Hospital,

Abha, Saudi Arabia

Summary

This report describes a 16-year old female patient who presented with acute paresis in both lower limbs, acute urinary retention, blurred vision and arthritis. The patient was diagnosed as having systemic lupus erythematosus with myelitis and bilateral abducent nerves palsy. The administration of steroids resulted in marked improvement in her neurological symptoms.

Key words: Systemic Lupus Erythematosus, Neuropsychiatric, Myelopathy, Corticosteroids.

Résumé

Ce rapport tâche de décrire une patiente âgée de 16 ans qui s'est présentée atteinte du paresis chronique dans les deux membres inférieurs, rétention de l'urine chronique, vue trouble, et l'arthrite. La patiente a été diagnostiquée atteinte du lupus erythemateu systemique avec la myelite et la paralysie abducent des nerfs bilateraux, (bilateral abducent nerves palsy). L'administration des stéroides a provoqué une amélioration remarquable dans ses symptômes neurologiques.

Introduction

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder of unknown cause affecting mainly women of childbearing age¹. SLE can affect the skin, joints, kidneys, lungs, nervous system, serous membranes and/or other organs of the body. Distinct immunologic abnormalities, especially the production of a number of antinuclear antibodies, are other prominent features of the disease. The clinical course of SLE is characterized by periods of remissions and chronic or acute relapses. Treatment is based on preventive measures, reversal of inflammation, prevention of organ im-

pairment, and alleviation of symptoms²⁻⁴.

Central nervous system (CNS) involvement has been reported to occur in 14 to 75 % of patients with SLE⁵⁻⁶. Myelopathy is a well recognized, but infrequent and serious neurological manifestation of systemic lupus erythematosus, occurring in less than 1% of SLE patients⁷.

In this case report we demonstrate the clinical features in a 16 year old Saudi female who presented with systemic lupus erythematosus with myelopathy, peripheral neuropathy and cranial nerve lesion (bilateral abducent nerves), successfully treated with pulse and oral corticosteroid therapy.

Case report

A 16-year-old Saudi girl presented to the Emergency Room of Assir Central hospital, Abha, Saudi Arabia on 9 July 2002 with a sudden attack of blurred vision, retention of urine and inability to walk. Her condition started 2 years ago with recurrent attacks of mild unilateral headache managed successfully with analgesics in the local primary health center as a case of migraine. Two months prior to admission, her headache progressed in severity, became continuous, generalized, and was associated with non-projectile vomiting. In the preceding one month, she started having blurring of vision and double vision which occurred when looking extremely to the left or right side. The patient's relatives also noticed squinting of her left eye. At this time, she started having unusual hair fall, asymmetrical joint pain and swelling involving small joints of the hands and feet, elbows, knees and ankles. For the last 25 days she has had a rapidly progressive low back pain, not radiating or related to cough or straining but associated with paraesthesia of both lower limbs. In the 24 hours preceding her admission the patient had retention of urine with marked weakness in her lower limbs




Fig. 1 Partial abducent nerve palsy. The left side is more involved than the right side

*Correspondence




Fig. 2 MRI of the lumbo-sacral spine (A) and the brain (B). No lesions are evident.

associated with inability to walk. On examination, she was conscious, well oriented, looked ill, was in pain, but was neither pale, cyanosed nor jaundiced. She was not in respiratory distress. There were no palpable peripheral lymph nodes, no skin rash, no digital clubbing. There was no lower limb edema and the jugular vein pressure was not raised. Her vital signs were normal BP= 110/70/mmHg, Heart rate 72 beat/minute). Chest, cardiovascular and abdominal examinations revealed no abnormalities. Right knee and left ankle effusion were present. Central nervous system showed bilateral abducent nerve lesions (Fig. 1). There was hypotonia involving both lower limbs with decreased power bilaterally (right side (1-2/5) more than the left side (4/5) in all muscle groups). Knee and ankle reflexes were brisk bilaterally. Plantar reflex was flexor on the left side and extensor on the right side. Sensation was diminished in both feet.

Investigations. The ESR (112mmhg) was elevated, there was normocytic, hypochromic anemia (Hb=8.6 gm/dl), lymphopenia, and mild proteinuria (280mg/24hours) with normal kidney function. Antinuclear antibody (ANA) and anti double stranded deoxyribonucleic acid (dsDNA) were positive, but cytoplasmic antineutrophil cytoplasmic antibody (cANCA) and perinuclear antineutrophil cytoplasmic antibody (pANCA) were negative. Serum complement C4 and C3 were low (C4 = 6.44mg/dl, C3 = 24.4mg/dl). The spinal fluid analysis was normal. Plain chest radiography, plain X-ray of the spine and abdominal ultrasound scan were all normal. Magnetic Resonant Imaging (MRI) of the brain and spine were within normal limits (Fig.2). Electromyography (EMG) and nerve conduction studies showed a mixed picture of peripheral neuropathy and myopathy. Treatment was started with pulse methylprednisolone therapy (1 gm / intravenous) for three successive days followed by daily oral prednisolone (1mg/Kg) for another one month. The patient showed progressive neurological and arthritic improvement with gradual decreasing in her ESR (46mmHg on discharge) and was discharged on 18 August 2003 with adequate power in her

lower limbs (power 4/5), residual abducent dysfunction. She is continued on oral corticosteroid (40 mg/day) and physiotherapy program.

Discussion

Systemic lupus erythematosus (SLE) has been known for almost a century and remains the prototypic immune disease⁸. SLE predominantly affects women and is more common in blacks⁸. Although survival rates have improved, over one-half of patients with systemic lupus erythematosus have permanent damage in one or more organ systems. Arthritis and cutaneous manifestations are the most common presentations, but renal, haematologic and neurologic manifestations contribute largely to mortality and morbidity⁸.

Central nervous system involvement in SLE is frequent and severe⁹. However, myelopathy is rarely reported⁹, occurring most often during the course of the disease¹⁰. Although magnetic resonance imaging (MRI) is the modality of choice for diagnosis of myelopathy. It shows signal abnormalities, usually T2 hypersensitivity, focal or extensive gadolinium enhancement and sometimes cord swellings. However about 40 % of acute transverse myelopathies remain undemonstrated¹¹. In our case MRI of the spine and brain were normal. Zenone et al.,¹⁰ reported that MRI findings depend on the timing of the examination and the stage of the disease, the MRI may therefore be normal¹¹.

The treatment of patient with neuropsychiatric lupus can be difficult and complex owing to the variety of nervous system manifestations that can occur¹². Also, the best treatment protocol has not yet been agreed on¹⁰. Currently, there is controversy about cyclophosphamide and methylprednisolone for the treatment of neuropsychiatric manifestations. In the patient presented, treatment with pulse methylprednisolone followed by a high dose of oral corticosteroids produced marked clinical improvement.

Although there are many recommendations in the

literature suggesting aggressive therapy with steroids and cyclophosphamide to get best outcome, Trevisani et al.,¹³ concluded in their review that cyclophosphamide treatment regimen in neuropsychiatric involvement in SLE has no evidence to show superior effectiveness and safety when compared with methylprednisolone¹³.

Conclusion

In the case presented, early treatment with high intravenous doses of corticosteroids, was effective and produced a good outcome in this SLE patients with neuropsychiatric manifestations.

References

1. Williams FMK, Chinn S, Hughes GRV, Leach RM. Clinical illness in systemic lupus erythematosus and the antiphospholipid syndrome. *Ann Rheum Dis* 2002; 5: 414-421.
2. Boumpas DT, Austin HA III, Fessler BJ, et al. Systemic lupus erythematosus: Emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. *Ann Intern Med* 1995; 122:940 .
3. Boumpas DT, Fessler BJ, Austin HA III, et al. Systemic lupus erythematosus: Emerging concepts. Part 2: Dermatological and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality and pathogenesis. *Ann Intern Med* 1995;123:42.
4. Mills JA. Systemic lupus erythematosus. *N Engl J Med* 1994; 330:1871 .
5. McCune WJ, Golbus J, Neuropsychiatric Lupus. *Rheum Dis North Am* 1988; 14: 149-67.
6. Hanly JG, Liang MH. Cognitive disorders in systemic lupus erythematosus. Epidemiological and clinical issues. *Ann N Y Acad Sci* 1997; 823:60-8.
7. Yang TF, Lee SS, Lin PH, Chen H, Chan RC. Effect of selective posterior rhizotomy on transverse myelitis in patient with systemic lupus erythematosus. *AMJ of Phys Med Rehabil* 2002; 81: 467-8.
8. Petry M. Treatment of systemic lupus erythematosus: An update. *The American Family Physician*. 1998;11:2753-62
9. Feki I, Ben-Hamida M, Masmoudi H, Triki C, Bahloul Z, Hachicha J, Jlidi R, Mhiri C. Lupic spinal cord disease and antiphospholipid antibodies. *Rev Neurol Paris*. 1997; 153:138-40
10. Zenone T, Steiner MP, Sibille M, Durieu I, Vital Durand D. Myelopathy revealing lupus. Two cases and review of the literature. *Rev Med Interne* 2000; 21: 1114-20.
11. Scotti G, Gerevini S. Diagnosis and differential diagnosis of transverse myelopathy. The role of neuroradiological investigations and review of the literature. *Neurol Sci* 2001; 22 Suppl 2:S69-73.
12. Navarrete MG, Brey RL. Neuropsychiatric Systemic Lupus Erythematosus. *Curr Treat Options Neurol* 2000; 2: 437-485 .
13. Trevisani VF, Castro AA, Nerves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. . *Cochrane Database Syst Rev* 2000; CD002265.